Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 96INDUSTRY 48NIH 13NETWORK 4OTHER_GOV 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 1Leukemia, Myeloid, Accelerated Phase 1

Interventions

fludarabine 5Cyclophosphamide 5Azacitidine 4Cytarabine 3venetoclax 2pegylated granulocyte colony-stimulating factor 2bisantrene 2Metformin 2Etoposide 2Dasatinib 2Clofarabine 2Busulfan 2vosaroxin 1treosulfan 1peginterferon alfa-2a 1nilotinib 1liposomal amphotericin B 1fludarabine phosphate 1defactinib 1decitabine and cedazuridine drug combination 1cedazuridine 1cc-486 1aldesleukin 1Zinc Sulfate 1Zinc 1Vitamin D 1Urination 1Tranexamic Acid 1Thiotepa 1Thalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER_GOV × Dasatinib × Other hematologic neoplasm × Clear all
NCT03414450 2018-10-25

Evaluation of ETC-1907206 With Dasatinib in Advanced Haematologic Malignancies

EDDC (Experimental Drug Development Centre), A*STAR Research Entities

Phase 1 Withdrawn
Other hematologic neoplasm

Leukemia, Myeloid, Accelerated Phase

NCT02113319 2014-04-14

DasaCBF

University Hospital, Angers

Phase 2 Completed
27 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡